What Is Gestational Diabetes?

Gestational diabetes mellitus (GDM) is a condition of glucose intolerance that is first recognized during pregnancy. It typically emerges in the second or third trimester, when hormonal changes from the placenta can interfere with the body’s ability to use insulin effectively—a phenomenon known as insulin resistance. When the pancreas cannot produce enough extra insulin to overcome this resistance, blood sugar levels rise abnormally.

GDM affects about 6–9% of pregnancies in the United States, though rates vary by population and diagnostic criteria used. Risk factors include being overweight or obese before pregnancy, having a family history of type 2 diabetes, being over age 25, having had GDM in a prior pregnancy, or belonging to certain ethnic groups (such as African American, Hispanic, Native American, or Asian American).

If untreated or poorly managed, gestational diabetes can lead to serious complications for both mother and baby. Maternal risks include a higher chance of developing preeclampsia (dangerously high blood pressure during pregnancy), urinary tract infections, and an increased likelihood of requiring a cesarean delivery. For the baby, GDM can cause macrosomia (excessive birth weight), which raises the risk of shoulder dystocia during birth, neonatal hypoglycemia, and later development of obesity and type 2 diabetes.

Why Diagnosis Matters: The Stakes of Early Detection

Detecting gestational diabetes early is not just a routine checkbox—it can change the trajectory of a pregnancy. The primary goal of screening and diagnosis is to identify women with hyperglycemia so that interventions can begin promptly. These interventions help keep blood glucose levels within a target range, reducing the risk of complications.

  • Maternal health: Well-controlled blood sugar lowers the risk of preeclampsia, preterm labor, and the need for operative delivery.
  • Fetal and neonatal health: Prevents macrosomia, birth trauma, and neonatal hypoglycemia. It also reduces the baby’s lifelong risk of metabolic syndrome and type 2 diabetes.
  • Future health for the mother: Women with GDM have a 40–60% chance of developing type 2 diabetes within 5–10 years after delivery. A diagnosis provides an opportunity for postpartum screening and lifestyle changes that can delay or prevent progression.

Universal screening is recommended by major health organizations, including the American College of Obstetricians and Gynecologists (ACOG) and the American Diabetes Association (ADA). For most pregnant women, testing occurs between 24 and 28 weeks of gestation—a window when insulin resistance typically becomes significant.

Who Should Be Tested for Gestational Diabetes?

There are two approaches to screening: universal screening for all pregnant women, and selective screening based on risk factors. In the United States, universal screening is the standard. However, some organizations suggest early screening for women with high-risk factors—such as a body mass index greater than 30, previous GDM, or known impaired glucose metabolism—at the first prenatal visit.

If early screening is negative, the woman is retested at 24–28 weeks. If early screening is positive, she may already have pre-existing type 2 diabetes that was previously undiagnosed, and management is adjusted accordingly.

Risk Stratification and Early Testing

Early screening (before 24 weeks) is generally reserved for women with one or more of the following:

  • BMI ≥ 30 kg/m²
  • Prior history of GDM
  • Known impaired glucose tolerance or impaired fasting glucose
  • First-degree relative with type 2 diabetes
  • Previous baby weighing more than 9 pounds (macrosomia)

If early screening is negative, the woman returns for routine screening at 24–28 weeks. If early screening is positive, she undergoes an oral glucose tolerance test (OGTT) to distinguish between overt diabetes and GDM.

The Physiology of Glucose Metabolism in Pregnancy

To understand why screening is timed as it is, it helps to know what happens to glucose metabolism during pregnancy. The placenta produces hormones such as human placental lactogen, growth hormone, cortisol, and progesterone. These hormones make maternal cells less sensitive to insulin—a natural adaptation designed to shunt glucose to the growing fetus. In many women, the pancreas compensates by producing enough extra insulin. However, in women who develop GDM, the compensatory increase is insufficient, leading to hyperglycemia.

This insulin resistance typically becomes most pronounced around the 20th to 24th week of gestation and continues to increase until delivery. That is why the recommended screening window falls at 24–28 weeks. Testing too early may miss women who have not yet developed resistance; testing too late may delay interventions that could prevent complications.

Placental Hormones and Insulin Resistance

Human placental lactogen (hPL) is a key driver of insulin resistance. Secreted in large quantities after the 20th week, hPL reduces maternal insulin sensitivity by altering insulin signaling pathways. Maternal progesterone and cortisol also contribute. The overall effect is to raise maternal blood glucose levels, providing a steady supply of glucose to the fetus. In a pregnancy without GDM, the maternal pancreas produces enough insulin to keep glucose within normal bounds. In a pregnancy with GDM, the beta cells fail to keep up.

The Screening Process: Two Key Tests

Glucose Challenge Test (GCT)

The GCT is a simple, non-fasting screening test. The patient drinks a solution containing 50 grams of glucose. After exactly one hour, a blood sample is drawn to measure the plasma glucose level. The test does not require fasting, though many providers advise avoiding sugary or high-carbohydrate meals in the hours beforehand to reduce false-positive rates.

Threshold: A value of 130–140 mg/dL is commonly used as the cutoff for an abnormal result (depending on the laboratory protocol). If the result is at or above this level, the test is considered positive, and a follow-up diagnostic test—the oral glucose tolerance test (OGTT)—is necessary.

Note: A positive GCT does not automatically mean a woman has gestational diabetes. It simply means her body may be having trouble processing the sugar load, and further testing is needed to confirm.

Oral Glucose Tolerance Test (OGTT)

The OGTT is the definitive diagnostic test for gestational diabetes. It requires more preparation and is more time-consuming, taking about three hours. The steps are:

  1. The woman must fast overnight (8–14 hours) before the test. Only water is allowed.
  2. Upon arrival at the lab or clinic, a baseline fasting blood sugar level is drawn.
  3. She then drinks a solution containing 75 or 100 grams of glucose (depending on the protocol used). The 100-gram solution is typical for the three-hour test recommended by ACOG; the 75-gram solution is used for the two-hour test recommended by the International Association of Diabetes and Pregnancy Study Groups (IADPSG).
  4. Blood samples are taken at intervals: at 1 hour, 2 hours, and (for the three-hour test) 3 hours after the drink.

The patient remains seated and does not eat, drink, or exercise during the testing period, as any of these could alter the results.

Interpreting Test Results: Diagnostic Criteria

Interpretation depends on which set of criteria the healthcare provider follows. In the United States, the two most common systems are the Carpenter-Coustan criteria (based on the 100-gram OGTT) and the IADPSG criteria (based on the 75-gram OGTT).

Carpenter-Coustan Criteria (Three-Hour Test)

Using the 100-gram oral glucose load, gestational diabetes is diagnosed when two or more of the following thresholds are met or exceeded:

  • Fasting: 95 mg/dL or higher
  • 1 hour: 180 mg/dL or higher
  • 2 hours: 155 mg/dL or higher
  • 3 hours: 140 mg/dL or higher

These thresholds are slightly stricter than the older National Diabetes Data Group criteria.

IADPSG/WHO Criteria (Two-Hour Test)

Using the 75-gram glucose load, the diagnosis is made if any one of these values is met or exceeded:

  • Fasting: 92 mg/dL or higher
  • 1 hour: 180 mg/dL or higher
  • 2 hours: 153 mg/dL or higher

The IADPSG criteria are more sensitive, meaning they will catch more cases of GDM—potentially increasing the diagnosed prevalence to 15–20% of pregnancies in some populations. This approach is endorsed by the World Health Organization and the ADA, though it has been debated due to concerns about overdiagnosis and resource burden.

Additional Diagnostic Systems Worldwide

Outside the United States, other criteria are in use. For example, the United Kingdom uses the World Health Organization (WHO) 2013 criteria, which are essentially the IADPSG thresholds. Australia and New Zealand have adopted similar guidelines. Some countries still rely on the older O’Sullivan criteria or the National Diabetes Data Group (NDDG) thresholds, which are less sensitive. When traveling or moving between countries during pregnancy, it helps to be aware of local practices.

One-Step vs. Two-Step Screening Approaches

The choice between a one-step or two-step strategy is a matter of ongoing clinical debate:

  • Two-step approach: GCT followed by OGTT if positive. This is the traditional method favored by ACOG. It reduces the number of full OGTTs needed and may be more practical in busy clinics.
  • One-step approach: A single 75-gram OGTT performed at 24–28 weeks. This directly diagnoses GDM based on IADPSG criteria without a preliminary screening test. The ADA and WHO prefer this method, arguing it identifies more women at risk.

Both approaches are valid. The decision often depends on local guidelines, patient population, and resource availability.

Evidence from Large Trials

The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, a landmark multinational trial published in 2008, provided the foundation for the IADPSG criteria. HAPO showed a continuous linear relationship between maternal blood sugar levels and adverse outcomes such as macrosomia, cesarean delivery, and neonatal hypoglycemia. That data influenced the shift toward more sensitive diagnostic thresholds. However, critics argue that the IADPSG thresholds increase healthcare costs without clear evidence that treating mild hyperglycemia improves outcomes. Ongoing research continues to refine the optimal screening strategy.

Preparing for the Tests: Practical Tips

To ensure accurate results, women scheduled for an OGTT should follow their healthcare provider’s instructions carefully:

  • Consume a balanced diet containing at least 150 grams of carbohydrates per day for the three days preceding the test. A low-carb diet before the test can falsely elevate glucose levels due to metabolic stress.
  • Fast for 8–14 hours before the test. Water is allowed, but no food, juice, coffee, or other beverages.
  • Avoid intense physical activity in the 24 hours before the test.
  • Bring a snack or meal to eat immediately after the test, as blood sugar may drop.

Some women experience nausea or lightheadedness after drinking the glucose solution. If vomiting occurs early, the test may need to be rescheduled. Letting the lab know ahead of time about any history of hypoglycemia or bariatric surgery can also help them prepare.

After a Diagnosis: What Happens Next?

A diagnosis of gestational diabetes can feel overwhelming, but it is a manageable condition. The first step is a comprehensive consultation with the obstetrics team and often a registered dietitian or certified diabetes care and education specialist.

Management strategies include:

  • Medical nutrition therapy: A diet focused on balanced carbohydrates, adequate protein, healthy fats, and fiber. Meals are spaced every 2–3 hours to prevent blood sugar spikes and crashes. Carbohydrate counting is often taught.
  • Blood glucose monitoring: Women are asked to check their blood sugar four times a day—fasting and one hour after each meal. Target ranges are typically ≤95 mg/dL fasting and ≤140 mg/dL one hour post-meal.
  • Physical activity: Moderate exercise, such as walking for 30 minutes after meals, helps lower blood glucose. Providers may recommend specific precautions based on the pregnancy.
  • Medication: If diet and exercise are insufficient to keep glucose levels in range, medication is prescribed. Insulin is the first-line treatment recommended by ACOG because it does not cross the placenta. Some providers also use oral agents like metformin or glyburide, though these have more debate around safety.

Women with GDM also receive more frequent prenatal visits and additional fetal surveillance (such as ultrasound to monitor fetal growth and non-stress tests in the third trimester). Induction of labor before 40 weeks may be considered if the baby is large or if glucose control is poor.

The Role of Continuous Glucose Monitoring

For some women, traditional finger-stick checks may be supplemented with continuous glucose monitors (CGMs). These devices provide real-time data on glucose trends and can help identify postprandial spikes or overnight hypoglycemia. While CGMs are not yet standard in GDM management, they are gaining interest as technology becomes more accessible.

Postpartum Follow-Up: Don’t Forget the Future

Gestational diabetes usually resolves after delivery, but the metabolic risk persists. All women who had GDM should undergo a 2-hour 75-gram OGTT at 4–12 weeks postpartum to screen for persistent type 2 diabetes or prediabetes. This follow-up is critical because many women transition to type 2 diabetes without symptoms.

Long-term, maintaining a healthy weight, staying physically active, and getting regular check-ups are the best strategies to reduce the risk of developing type 2 diabetes. The Centers for Disease Control and Prevention (CDC) offers a National Diabetes Prevention Program that can be particularly helpful.

For future pregnancies, women with a history of GDM should be screened early in the pregnancy and again at 24–28 weeks. Lifestyle interventions between pregnancies can significantly lower the chance of recurrence.

Lactation and GDM

Breastfeeding is encouraged for women with a history of GDM. Studies suggest that lactation improves maternal glucose metabolism and may reduce the risk of future type 2 diabetes. Women who breastfeed for at least three months postpartum have been shown to have lower fasting glucose and insulin levels.

Potential Complications if Untreated

Undiagnosed or poorly managed gestational diabetes can lead to serious consequences:

  • Preeclampsia: High blood pressure that can affect the placenta and cause damage to the mother’s kidneys, liver, or brain.
  • Polyhydramnios: Excessive amniotic fluid, which can increase the risk of preterm labor and postpartum hemorrhage.
  • Macrosomia and birth trauma: A large baby may require a difficult delivery, increasing the risk of shoulder dystocia and fractures.
  • Neonatal hypoglycemia: The baby’s pancreas may overproduce insulin in response to the mother’s high glucose, leading to dangerously low blood sugar after birth.
  • Stillbirth: Although rare with current surveillance, poor glucose control is associated with an increased risk of late stillbirth.

These complications reinforce why universal screening and timely diagnosis are essential components of modern prenatal care.

External Resources and Guidelines

For readers seeking more detailed information, the following authoritative sources are recommended:

Understanding the diagnostic process for gestational diabetes empowers expectant mothers to participate actively in their prenatal care. From the initial glucose challenge test to comprehensive management and postpartum follow-up, every step is designed to protect the health of both mother and child. With proper attention, the vast majority of women with GDM go on to deliver healthy babies and maintain good long-term health.